Alnylam Pharmaceuticals Inc., of Cambridge, Mass., reported preclinical data published in Experimental Neurology showing that a small interfering RNA (siRNA) targeting the huntingtin gene resulted in widespread distribution of the siRNA when administered by intrastriatal infusion using convection-enhanced delivery and demonstrated significant silencing of the huntingtin mRNA throughout the striatum.